Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
Key Highlights
- ➤Cash, equivalents and marketable securities totaled $193.3 million at September 30, 2026
- ➤IMPROVE-PAH secured 28 country approvals, with 79 of 180 sites activated
- ➤Q3 net loss widened to $20.5 million from $11.9 million year over year
- ➤Q3 R&D expenses nearly doubled to $15.0 million from $7.6 million
- ➤FDA granted IKT-001 Orphan Drug Designation in July 2026
Expert Statements
Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries.”
Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics
“We continue to expand our clinical footprint and look forward to additional country and site activations over the coming months.”
Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics
“Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments.
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We continue to expand our clinical footprint and look forward to additional country and site activations over the coming months. Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”
Get started
Create a free account to read the full story.